Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about House Select Committee on China
Every one of those 1 sits in a single category, regulation. Brookings Institution is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window. Their average consequence score of 8 runs above the beat's 6.5 for that window. House Select Committee on China appears in 1 tracked Legal story from March 19, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 45 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering House Select Committee on China. Shared-story counts are live from our verified record — not editorial picks.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.
House Select Committee on China is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.